Layoffs hit J&J, Bristol Myers Squibb, Bayer (updated)
WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline operations.
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite potential risks. Read more on BMY here.
Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb
Prime Medicine shares rose on Monday after the company signed a research collaboration and license agreement Bristol Myers Squibb to develop reagents for T-cell therapies. In premarket trading, shares were up 20% to $4.
Prime Medicine Inks Strategic Research Collaboration And License Agreement With Bristol Myers Squibb
Prime Medicine, Inc. (PRME) announced Monday a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY)
Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb
Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is rarely straightforward.
Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which includes a $55M equity investment. Read more here.
Law1d
Bristol-Myers Squibb Wins Dismissal of $6.4 Billion Lawsuit Alleging Intentional Delay of Cancer Drug
A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol-Myers Squibb Co., agreeing with counsel for ...
Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...
The Gazette3d
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene ...
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
bovnews2d
BMY’s Latest Twist: What’s Fueling the Unexpected Shifts in Bristol-Myers Squibb Co’s Stock Price?
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3
The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), tracking the healthcare companies under S&P 500, rose 6.27% in ...
Bristol Myers Squibb Marks 10 Years of Global Patient Week with Community Initiatives in the Region
To mark the 10th anniversary of its Global Patient Week, Bristol Myers Squibb, a leading global biopharmaceutical company, ...